News Releases

Media Contact: Lissa Pavluk media@apellis.com (617) 977-6764

December 20, 2018 Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy
December 20, 2018 Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
December 3, 2018 Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
December 2, 2018 Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
November 20, 2018 Apellis Pharmaceuticals Expands Leadership Team, Appoints Adam Townsend as Chief Commercial Officer
November 13, 2018 Apellis Pharmaceuticals Reports Third Quarter 2018 Business Update and Financial Results
November 7, 2018 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
November 1, 2018 Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
September 28, 2018 Apellis Pharmaceuticals to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
September 12, 2018 Apellis Pharmaceuticals Announces First Patient Dosed in Its Phase 3 Clinical Program for APL-2 in Patients With Geographic Atrophy